Ironwood Pharmaceuticals (IRWD) Competitors $0.82 -0.05 (-5.49%) Closing price 04:00 PM EasternExtended Trading$0.82 +0.00 (+0.05%) As of 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock IRWD vs. ABBV, LXRX, MYGN, EBS, RIGL, XOMA, VSTM, VNDA, CBIO, and CDXSShould you be buying Ironwood Pharmaceuticals stock or one of its competitors? The main competitors of Ironwood Pharmaceuticals include AbbVie (ABBV), Lexicon Pharmaceuticals (LXRX), Myriad Genetics (MYGN), Emergent Biosolutions (EBS), Rigel Pharmaceuticals (RIGL), XOMA Royalty (XOMA), Verastem (VSTM), Vanda Pharmaceuticals (VNDA), Crescent Biopharma (CBIO), and Codexis (CDXS). These companies are all part of the "medical" sector. Ironwood Pharmaceuticals vs. Its Competitors AbbVie Lexicon Pharmaceuticals Myriad Genetics Emergent Biosolutions Rigel Pharmaceuticals XOMA Royalty Verastem Vanda Pharmaceuticals Crescent Biopharma Codexis AbbVie (NYSE:ABBV) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends. Do insiders and institutionals believe in ABBV or IRWD? 70.2% of AbbVie shares are owned by institutional investors. 0.3% of AbbVie shares are owned by company insiders. Comparatively, 12.7% of Ironwood Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts rate ABBV or IRWD? AbbVie presently has a consensus price target of $211.29, indicating a potential upside of 10.71%. Ironwood Pharmaceuticals has a consensus price target of $4.78, indicating a potential upside of 483.62%. Given Ironwood Pharmaceuticals' higher probable upside, analysts clearly believe Ironwood Pharmaceuticals is more favorable than AbbVie.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AbbVie 0 Sell rating(s) 8 Hold rating(s) 16 Buy rating(s) 3 Strong Buy rating(s) 2.81Ironwood Pharmaceuticals 0 Sell rating(s) 7 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.13 Which has better valuation & earnings, ABBV or IRWD? AbbVie has higher revenue and earnings than Ironwood Pharmaceuticals. Ironwood Pharmaceuticals is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbbVie$57.37B5.88$4.28B$2.3581.21Ironwood Pharmaceuticals$351.41M0.38$880K-$0.20-4.10 Is ABBV or IRWD more profitable? AbbVie has a net margin of 7.31% compared to Ironwood Pharmaceuticals' net margin of -9.89%. AbbVie's return on equity of 412.03% beat Ironwood Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets AbbVie7.31% 412.03% 13.11% Ironwood Pharmaceuticals -9.89%-1.87%-3.93% Which has more risk and volatility, ABBV or IRWD? AbbVie has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500. Comparatively, Ironwood Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500. Does the media refer more to ABBV or IRWD? In the previous week, AbbVie had 72 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 76 mentions for AbbVie and 4 mentions for Ironwood Pharmaceuticals. AbbVie's average media sentiment score of 1.15 beat Ironwood Pharmaceuticals' score of 0.96 indicating that AbbVie is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbbVie 53 Very Positive mention(s) 5 Positive mention(s) 15 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Ironwood Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAbbVie beats Ironwood Pharmaceuticals on 15 of the 17 factors compared between the two stocks. Get Ironwood Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IRWD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IRWD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IRWD vs. The Competition Export to ExcelMetricIronwood PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$140.33M$2.52B$5.70B$9.48BDividend YieldN/A1.76%4.59%3.99%P/E Ratio-4.109.1227.9019.95Price / Sales0.38746.51442.18102.66Price / Cash17.53166.2336.5558.97Price / Book-0.445.228.635.90Net Income$880K$30.99M$3.24B$258.42M7 Day Performance3.64%4.29%3.22%1.94%1 Month Performance12.92%13.40%10.72%12.02%1 Year Performance-87.68%0.59%34.94%20.81% Ironwood Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IRWDIronwood Pharmaceuticals4.3455 of 5 stars$0.82-5.5%$4.78+483.6%-87.2%$140.33M$351.41M-4.10220News CoverageABBVAbbVie4.8796 of 5 stars$184.77-2.4%$211.29+14.4%+9.9%$334.31B$56.33B78.6255,000Positive NewsUpcoming EarningsLXRXLexicon Pharmaceuticals2.5735 of 5 stars$1.23flat$3.67+198.1%-45.5%$444.64M$31.08M0.00140Upcoming EarningsMYGNMyriad Genetics4.4841 of 5 stars$4.45-0.4%$14.38+223.2%-83.1%$412.03M$837.60M0.002,700EBSEmergent Biosolutions4.3305 of 5 stars$6.93+0.0%$14.33+106.8%-38.7%$376.14M$1.04B-2.562,420Positive NewsRIGLRigel Pharmaceuticals3.2182 of 5 stars$19.59+4.2%$36.40+85.8%+100.1%$336M$179.28M9.08160Positive NewsXOMAXOMA Royalty3.9286 of 5 stars$25.48-0.7%$69.50+172.8%-10.2%$307.19M$28.49M0.0010VSTMVerastem3.5304 of 5 stars$5.10-1.2%$13.38+162.3%+49.0%$283.54M$10K0.0050VNDAVanda Pharmaceuticals4.5983 of 5 stars$4.66-2.5%$16.50+254.1%-23.2%$281.71M$198.77M-6.21290News CoverageUpcoming EarningsCBIOCrescent Biopharma3.3374 of 5 stars$13.20-1.0%$25.67+94.4%N/A$260.79M$10K-0.2950CDXSCodexis2.9193 of 5 stars$2.84+0.7%$11.00+287.3%-9.8%$233.62M$59.35M-2.87250 Related Companies and Tools Related Companies AbbVie Alternatives Lexicon Pharmaceuticals Alternatives Myriad Genetics Alternatives Emergent Biosolutions Alternatives Rigel Pharmaceuticals Alternatives XOMA Royalty Alternatives Verastem Alternatives Vanda Pharmaceuticals Alternatives Crescent Biopharma Alternatives Codexis Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IRWD) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersElon Just Fired the IRS Agents Targeting Your SavingsElon Musk just fired 6,700 IRS agents — and exposed a war on your retirement. While D.C. scrambles to regai...Priority Gold | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredBREAKING: The House just passed 3 pro-crypto bills!99.8% voted YES on this crypto partnership Kraken—one of the world's biggest crypto exchanges—just picked O...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredThe big winner of Crypto week?It’s Crypto Week at the White House — and the sector is moving from fringe to full-scale adoption. With Bit...Weiss Ratings | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ironwood Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ironwood Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
